Beschreibung
Fluoxetine plus sumatriptan may potentiate serotonin syndrome risk, though the clinical evidence is mixed and the absolute risk is debated.
Mechanismus
Fluoxetine inhibits serotonin reuptake and is a potent CYP2D6 inhibitor which may modestly increase sumatriptan exposure; combined serotonergic activity raises theoretical serotonin syndrome risk.
Klinische Bedeutung
Post-marketing surveillance reports exist; many clinical guidelines permit the combination with monitoring, given frequent co-prescription in migraine.
Maßnahmen
Combination is commonly used; monitor for signs of serotonin syndrome especially at treatment initiation or dose escalation.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.